Pfizer’s claim of a human rights violation and its overt pressure on the government of the Dominican Republic as a strategy to protect its patent on Paxlovid has caused concern among shareholders that the board is putting Pfizer’s social license to operate at risk. In this letter, ICCR notes the incongruence between Pfizer’s stated principles related to access, its commitments in the company’s human rights policy statement, and its stated values and principles related to equity, with actions that seek to hinder access to life-saving COVID medicines.